Antibodies
23 September 2009
ImmunoCellular Therapeutics Announces Successful Humanization of Two Antibody Candidates22 September 2009
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients22 September 2009
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer21 September 2009
Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors21 September 2009
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases18 September 2009
Pancreatic and Colorectal Cancer Novel Antibody Developed from a Vaccine to Begin Phase I Trial18 September 2009
ArmaGen completes primate safety study for AGT-18117 September 2009
ImmunoGen Announces Amgen has Licensed Rights to Use the Company’s TAP Technology for a Solid Tumor Target17 September 2009
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance16 September 2009
Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis15 September 2009
Kenta Biotech Reports Phase IIa Data with Lead Candidate Panobacumab in Hospital-Acquired Pneumonia15 September 2009
Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)11 September 2009
Genzyme’s Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data9 September 2009
ImmunoCellular Therapeutics Enters into Research and License Option Agreement with Roche Group7 September 2009
Bristol-Myers Squibb Announces Acceptance of Submission for Belatacept Biologic License Application4 September 2009
FDA Approves ZEVALIN(R) Expanded Label as Part of First-Line Therapy in Treatment of Follicular Non-Hodgkin’s Lymphoma3 September 2009
MabThera approved in Europe for use in patients with previously-treated chronic lymphocytic leukaemia3 September 2009
Two New Antibodies Found to Cripple HIV1 September 2009
Ablynx Initiates Phase II Clinical Trial for Alx-00811 September 2009
Patient recruitment in Phase III registration trial with REDECTANE® successfully completed28 August 2009
Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU-016News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports